Novo Nordisk A/S

Hims & Hers Health, Inc.

U.S. site Hims &amp; Hers could announce a renewed partnership with Denmark's Novo Nordisk as soon as Monday

Shares of online pharmacy Hims &amp; Hers soared 40% amid a general sell-off. What is it?

Eli Lilly and Company

Merck & Co., Inc.

Pharmaceutical stocks could be one of the defensive assets amid the escalating conflict in the Middle East, analysts at UBS said, their note <a href="https://www.cnbc.com/2026/03/06/market-turmoil-is-hitting-traditional-safe-havens-ubs-says-hide-here-.html">quoted by</a> CNBC.

'Most defensive sector': UBS names stocks that can 'safely survive war'

VolitionRx Limited

Shares of VolitionRx, a micro-cap developer of blood tests for cancer and sepsis, <a href="https://finance.yahoo.com/quote/VNRX/">jumped</a>&nbsp;nearly 26% on Tuesday after the company <a href="https://ir.volition.com/news-events/press-releases/detail/874/volitionrx-highlights-commercial-momentum-and-multi-pillar-execution">reported</a>&nbsp;progress in several research programs and said a newly developed cancer-detection method has attracted interest from potential partners. The company also highlighted breakthrough research on detecting lymphoma in cats. Wall Street analysts <a href="https://www.marketwatch.com/investing/stock/vnrx/analystestimates?mod=mw_quote_tab">say</a>&nbsp;the stock could have nearly 790% upside.

Cancer blood test maker VolitionRX soars 25% in a day on reported commercial progress

Vir Biotechnology, Inc.

Shares of Vir Biotechnology, a small-cap developer of drugs for infectious diseases and cancer, <a href="https://finance.yahoo.com/quote/VIR/">soared</a>&nbsp;on Tuesday by almost 28% to reach their highest level in more than a year. The company provided a series of updates, which were described as amounting to a “<a href="https://investors.vir.bio/news/news-details/2026/Vir-Biotechnology-Provides-Corporate-Update-and-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results/default.aspx">seminal moment</a>” for Vir. They include, among other things, a <a href="https://investors.vir.bio/news/news-details/2026/Astellas-and-Vir-Biotechnology-Announce-Global-Strategic-Collaboration-to-Advance-PSMA-targeting-PRO-XTEN-Dual-masked-T-Cell-Engager-VIR-5500-for-the-Treatment-of-Prostate-Cancer/default.aspx">partnership</a>&nbsp;with Japan’s Astellas worth up to $1.71 billion. Against this backdrop, several investment banks <a href="https://finance.yahoo.com/quote/VIR/">raised</a>&nbsp;their target prices for Vir stock.

'Seminal moment': Biotech Vir sees shares jump over 25% amid flurry of announcements

Danish company Novo Nordisk <a href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916504">has announced</a> its intention to reduce list prices in the US for its flagship weight loss and diabetes drugs Wegovy and Ozempic. Their prices will be reduced by up to 50% starting next year, according to the company. Novo said it expects to increase the affordability of the therapy in this way, especially for those who pay for the treatment themselves - partially or fully.

Novo Nordisk to cut prices on weight loss products by up to 50%. Why is the stock falling?

Arcellx, Inc.

Gilead Sciences, Inc.

Shares of Arcellx, a mid-cap developer of cell therapies for blood cancers, <a href="https://finance.yahoo.com/quote/ACLX/">surged</a>&nbsp;77% on Monday to a new all-time high after the <a href="https://ir.arcellx.com/news/news-details/2026/Gilead-Sciences-to-Acquire-Arcellx-to-Maximize-Long-term-Potential-of-Anito-cel/default.aspx">announcement</a>&nbsp;that its major partner, Gilead Sciences, will acquire the company at a substantial premium to the market price. For investors, the deal signals that leading pharmaceutical companies increasingly prefer full ownership of late-stage oncology assets, Noble <a href="https://www.channelchek.com/news-channel/gilead-to-acquire-arcellx-in-7-8b-bet-on-next-gen-car-t-leadership">argues</a>.

Cancer drugmaker Arcellx explodes 77% in a day as Gilead will acquire it

NVIDIA Corporation

Coinbase Global, Inc.

ASML Holding N.V.

Amazon.com, Inc.

Nu Holdings Ltd.

Celestica Inc.

Super Micro Computer, Inc.

Taiwan Semiconductor Manufacturing Company Limited

Vale S.A.

Adani Enterprises Limited

Palantir Technologies Inc.

Petroleo Brasileiro S.A. - Petrobras

Rio Tinto Group

Rheinmetall AG

Reliance Industries Limited

Constellium SE

LVMH Moet Hennessy - Louis Vuitton, Societe Europeenne

71% of asset management firms plan to <a href="https://www.grantthornton.com/insights/articles/asset-management/2025/ai-is-transforming-asset-management">incorporate</a> generative AI into their operations, according to data from a survey of 500 senior investment industry executives in key global markets conducted by Grant Thornton in partnership with ThoughtLab. Two-thirds say the payoff in AI is still modest, and 12% see no return or negative results. I don't have access to the same resources and infrastructure as BlackRock, for example, or another large money manager. But if the majority is going to implement generative AI, it is logical to ask whether it can already fulfill a basic investment objective at the retail investor level today.

I gave three AI chatbots €500 to invest. Here's what they did with my money

A key objective of the trial was to confirm that Novo was as effective as a competitor's product, Eli Lilly

Novo's failure to test a weight loss drug has sparked a sell-off in the Danish market

Moderna, Inc.

Quotes have already risen 58% since the beginning of the year

A regulator in the US has had a dramatic change of heart on the new Moderna vaccine. Its shares rose 6%

The decrease in quotations in the moment was the strongest for nine months

Moderna's stock fell due to regulatory concerns. A more important development is also under attack

At issue is an unlicensed in the U.S. tablet version of the weight-loss drug Wegovy, which competitor Novo hoped to sell for several times cheaper than the original product

Novo shares rise: cheap copy of its drug fails to survive criticism from US regulator

Novo a day earlier, by contrast, had warned of a decline in sales

Pharmaceutical Companies